First Time Loading...

Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 656.5 DKK -0.53%
Updated: May 9, 2024

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 805.04 DKK with a low forecast of 606 DKK and a high forecast of 882 DKK.

Lowest
Price Target
606 DKK
8% Downside
Average
Price Target
805.04 DKK
23% Upside
Highest
Price Target
882 DKK
34% Upside
Zealand Pharma A/S Competitors:
Price Targets
KRRO
Korro Bio Inc
153% Upside
PRQR
ProQR Therapeutics NV
117% Upside
SWTX
SpringWorks Therapeutics Inc
61% Upside
4891
TMS Co Ltd
208% Upside
CSL
CSL Ltd
12% Upside
IVA
Inventiva SA
281% Upside
688278
Xiamen Amoytop Biotech Co Ltd
32% Upside
BIOPOR
Bioporto A/S
213% Upside

Revenue
Forecast

Revenue Estimate
Zealand Pharma A/S

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is 8%. The projected CAGR for the next 3 years is 79%.

8%
Past Growth
79%
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
805.04 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 805.04 DKK with a low forecast of 606 DKK and a high forecast of 882 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
79%

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is 8%. The projected CAGR for the next 3 years is 79%.